Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06384417 · ClinicalTrials.gov registry record · NA

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

A NA study of Breast Cancer and Lung Cancer, sponsored by Milton S. Hershey Medical Center.

Active
Registry status
NA
Development phase
32
Enrollment target
1
Study location

NCT06384417: Active NA study of Breast Cancer and Lung Cancer, sponsored by Milton S. Hershey Medical Center.

NCT06384417 is a NA study of Breast Cancer and Lung Cancer that is active but no longer recruiting, run by Milton S. Hershey Medical Center. The registered enrollment target is 32 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06384417, a NA study of Breast Cancer and Lung Cancer, is active but no longer recruiting, sponsored by Milton S. Hershey Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast, gastro-intestinal, lung, melanoma, head and neck, and/or genito-urinary cancers) treated at Penn State Health clinics and their loved ones perform advance care planning (ACP). The main questions it aims to answer are: What modifications and/or adaptations are necessary to Hello for use in cancer populations? What impact does participation in Hello event have on health care usage (e.g., number of hospitalizations, ICU admissions, emergency department visits, etc.)? How feasible is it to randomize participants to play either Hello for Cancer or Table Topics? Participants will: * Complete pre-game questionnaires * Play either Hello or Table Topics game * Complete post-game questionnaires * Participate in a focus group * Complete a telephone follow up interview 1-4 months after their event This study is a continuation of NCT06028152.

Primary Outcome

Focus groups will be conducted with individuals randomized to play the Hello for Cancer game. These focus groups will focus on learning about the participants' perception of playing the modified game and identified any questions that need additional modification.

Interventions

  • BEHAVIORAL Hello for Cancer game
  • OTHER Table Topics game

Study Locations (1)

Pennsylvania

  • Penn State Cancer Institute - Hershey

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-06-27
Est. Completion 2026-12
Phase NA
Milton S. Hershey Medical Center

396 total trials

What the registry record for NCT06384417 still lists

NCT06384417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Hello for Cancer game is the first listed.

NCT06384417 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06384417 about?

NCT06384417 is a clinical study titled "Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2". The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast, gastro-intestinal, lung, melanoma, head and neck, and/or genito-urinary cancers) trea...

What is the current status of trial NCT06384417?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2024-06-27. Estimated completion is 2026-12.

What conditions does trial NCT06384417 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Melanoma.

What interventions are being tested in trial NCT06384417?

The interventions under investigation include: Hello for Cancer game (BEHAVIORAL), Table Topics game (OTHER).

Who is sponsoring clinical trial NCT06384417?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06384417 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06384417's enrollment target sits among peer trials

32 941st of 1224 higher than 278 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06384417, the US trial registry maintained by the National Library of Medicine. NCT06384417 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.